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S_nary Mutation and abnormal expression of p53 was studied in 38 lymphomas [five Hodgidn's disease
and 33 non-Hodgkin's lymphoma (NHL)J. CMI polyclonal antibody was used to detect overexpression ofp53.
Thee missense mutations were characterised in three ca of NHL after exons 5-8 of p53 of all the
tumours with singlstd conformation polymorphism (SSCP) analysis. Only two out of three tumours with
a missense mutation showed abnormal expression of p53 as measured by CM1. Conversely, seven out of nine
tumours with positive CMI staining had no point mutation demonstrated. Overexpression of p53 in the cases
of NHL occurred in three out of twenty four low-grade tumours and five out of nine highp-gade tumours (Kid
classiiation). The results suggest that abnormalities ofp53 are commoner in high-grade than low-grade NHL,
and that positive immunocytochemistry cannot be used to determine which tumours have mutations of p53.
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Alteration in the p53 gene is the commonest genetic event
found in association with human neoplasia (Levine et al.,
1991) and often follows other genetic changes such as, in
colonic malignancy, c-ras activation and DNA hypomethyla-
tion (Marx, 1989). p53 seems to function as a specific trans-
cription activator and also patrols the genome for damage,
acting as a GI checkpoint control (Hartwell, 1992; Lin et al.,
1992). One of the key genes regulated is known by several
names (pici, WAFI, Cipl or Sdi) and produces p21 protein,
which inhibits cyclin-dependent phosphorylation of impor-
tant cell cycle regulators such as the product of the retinob-
lastoma gene (Levine, 1995).
p53 is also involved in apoptosis, possibly in those cells
which have sustained irreparable damage (Lane, 1992), and
mutation of this gene may partly explain the resiance of
certain tumours to cytotoxic agents (Levin, 1995). p53
appears to be crucial in damage control rather than normal
development. Apoptotic response to radiation damage
depends on normal p53 function - thymocytes from p53
knock-out mice are resistant to more than 20 Gy while cont-
rol thymocytes show apoptosis at 1 Gy (Lane, 1993). p53 is
also involved in the therapeutic response to the
topoisomerase 2 inhibitor, etoposide, by facilitating apoptosis
(Clarke et al., 1993).
Point mutation in highly conserved regions of p53 causes
loss of normal p53 protein function (Holstein et al., 1991).
p53 is a sequence-specific DNA-binding protein, and loss of
the ability to interact with DNA is common in mutant p53
proteins (El-Deiry et al., 1992). Murine models have shown
that p53 can be bound by mdm-2 protein (Momand et al.,
1992). The human homologue ofthis gene has been shown to
bind p53 in a way which switches off sequence-specific bin-
ding - high levels of mdm-2 may be tumorigenic by swit-
ching off p53, and many p53-associated proteins have been
identified (Pietenpol and Vogelstein, 1993). p53 protein may
function by accumulating in response to DNA damage,
thereby switching off replication to allow repair. Apoptosis is
triggered if DNA repair fails. Inactivation of p53 by any of
the methods outlined above would lead to accumulation of
mutations and the selection ofmalignant clones (Lane, 1992).
Studies on the murine p53 protein have shown that muta-
tions affecting over 43% of the protein from residues
120-290 are capable of activating p53 for cooperation with
ras in transforming cells (Levine, 1990).
In murine models, mutant p53 protein has an increased
half-life (from the normal 6-20 min to 4-8 h) and it is able
to complex the hsp70 family of heat shock proteins. Such
mutant proteins may also lose expression of the conforma-
tionally sensitive epitope recognised by the PAb 246 monoc-
lonal antibody and instead express the pan-species conforma-
tionally resistant epitope recognised by the PAb 240 antibody
(Lane and Benchimol, 1990).
The p53 gene spans 20kb of DNA on the short arm of
human chromosome 17 and has one non-coding exon located
several kilobases away from the ten coding exons (Levine,
1990). There are five blocks of evolutionarily conserved
amino acid sequence - the majority of mutations alter con-
served amino acids in four of these regions (Lane and Ben-
chimol, 1990), and much research has therefore concentrated
on the exons coding for these regions: 5, 6, 7 and 8.
Recently, an immense amount of work has been done to
characterise p53 mutations in relation to human neoplasia. In
lung cancer p53 has been found to be frequently mutated
(Takahashi et al., 1989) and is expressed abnormally (Iggo et
al., 1990). Mutation and abnormal expression has also been
shown in breast cancer (Coles et al., 1990; Thompson et al.,
1990), gastric carcinoma (Seruca et al., 1992), hepatocellular
carcinoma (Bressac et al., 1990) and many other tumour
types (Nigro et al., 1989).
Abnormal p53 function has been implicated in
haematological malignancies. Mice homozygous for a large
deletion within the p53 gene all develop tumours by the age
of 6 months, with a high incidence of T-cell lymphomas
(Purdie et al., 1994). Rearrangement of the gene associated
with abnormal p53 expression has been found in chronic
myeloid leukaemia (Ahuja et al., 1989; Mashal et al., 1990).
In Burkitt's lymphoma and its leukaemic counterpart muta-
tions of p53 may be associated with an activated c-myc
oncogene (Gaidano et al., 1991) and mutant p53 protein (as
detected by the monoclonal antibody PAb 240) is expressed
in Burkitt's lymphoma cell lines (Wiman et al., 1991). Bin-
ding of p53 to human papillomavirus (HPV) E6 protein
induces rapid degradation of p53. The presence of wild-type
p53 in HPV-positive tumours may indicate that E6 protein
binding obviates the need for p53 mutations in the genesis of
such tumours, but this association has not been noted with
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Epstein-Barr virus (EBV) infection and Hodgkin's disease
(Niedobitek et al., 1993). EBV immediate-early protein,
BZLF1, mediates lytic replication but can also interact with
p53. Immunosuppressed patients have a high frequency of
EBV-associated lymphomas, and more than half of these
lymphomas have cells which express BZLF1 protein. Inac-
tivation of p53 may unmask viral latency by preventing
interaction with this protein, but equally p53 function may
be inhibited by an excess of BZLF1 (Zhang et al., 1994).
Another EBV protein, EBNA-5 (EBNA-LP), is required for
B-cell transformation and can form complexes with both
wild-type and mutant p53 (Szekely et al., 1993).
When populations of haemopoietic cells are examined. p53
expression tends to decrease with increasing maturity of the
population (Kastan et al.. 1991). The progenitor cells as
characterised by CD34 and glycophorin positivity have
undetectable levels of p53 protein. In contrast, the non-
proliferating, mature cells have low but detectable levels of
the protein. Immortalised leukaemia cell lines express p53 in
a lineage specific manner, with lymphoid cell lines overex-
pressing and myeloid ones tending to lack expression.
Point mutation is associated with the detection of abnor-
mal p53 expression. but abnormality stabilised protein can
exist in the absence of p53 mutation (Wynford-Thomas,
1992). It is also not clear whether immunocytochemistry or
mutation analysis indicates the aggressiveness of a lym-
phoma. We have examined p53 with both mutation analysis
(direct sequencing) and with immunocytochemistry using a
polyclonal antibody (CM-1) in 38 lymphomas. CM-1 is
raised against the wild-type p53 protein (Midgley et al., 1992)
but is useful for detecting abnormally stabilised protein as
the short half-life of normal p53 protein makes it hard to
detect.
Materials and methods
Cases
Approval for the study was obtained from the local Joint
Ethics Committee. Tumour samples of Hodgkin's disease and
non-Hodgkin's lymphoma (NHL) were collected both fresh
from surgical theatres and from samples received in the
Department of Pathology, Aberdeen Royal Infirmary, from
1987 onwards and stored at -70°C. Most 'tumour' DNA
was extracted from frozen specimens, although some was
extracted from fresh samples from theatre before freezing. All
the pathological specimens (H&E and CMI stained) were
processed in the same way. The area of the specimen thought
most likely to be representative of the tumour was chosen for
these analyses. e.g. areas at the periphery of lymph nodes
which may have contained normal tissue were avoided. The
sections stained with CM1 polyclonal antibody were taken
from tumour immediately adjacent to that from which DNA
was extracted for SSCP analysis. This could not be
guaranteed for every H&E-stained section as some of these
were taken from the pathology archives. Cases were selected
on the basis that either fresh or archival frozen material was
available to provide sections for CM1 staining and also for
DNA extraction. The tumours were classified according to
the Kiel system (Lennert et al., 1983) and the Working
Formulation (Anonymous, 1982). The diagnoses of all
tumours were reviewed by one pathologist (WDT) who also
scored all the sections stained with CM1.
DNA extraction
DNA was extracted from tumour tissue using standard cell
lysis and phenol-chloroform purification techniques. The
specimens were stored at - 20'C if the DNA was not ext-
racted immediately. Genomic DNA stock was kept physically
separated from the area where the PCR reactions were
prepared.
Single-strand conformation polvmorphism (SSCP) analysis
Point mutations were sought in exons 5-8 of p53 using 25 ng
of template DNA in the amplification reactions and 10 pmol
of the following primer pairs:
exon 5 5'-TACTCCCCTGCCCTCAAC-3'
5'-GCCCCAGCTGCTCACCATCG-3'
exon 6 5'-GGCCTCTGATTCCTCACTGATT-3'
5'-AGAGACCCCAGTTGCAA-3'
exon 7 5'-CTTGCCACAGGTCTCCCCAA-3'
5'-AGGGGTCAGCGGCAAGCAGA-3'
exon 8 5'-TGCTTCTCTIT--CCTATCCTGA-3'
5'-CGCTTCTTGTCCTGCTTGCT-3'
The upstream primer of exon S was wholly exonic and the
downstream primer included the last five bases of the exon.
The other primers were wholly intronic. A 'master mix' was
used to increase accuracy: 10 x polymerase chain reaction
(PCR) buffer [Boehringer Mannheim. Lewis, UK:
100 mmol I' Tris-HCl. 15-mmol 1-P' magnesium chloride.
500 mmol I' potassium chlonrde. 1 mg ml'- gelatine. pH 8.3
(20'C)]; 'low C' nucleotide mix (nucleotides from Perkin
Elmer Cetus. Norwalk. CT, USA) using 10 mmol of dATP,
10 mmol of dGTP. 10 mmol of dTTP. 0.2 mmol of dCTP
and sterile water in a ratio of 1:1:1:1:4; 2 yI of a 1:12 dilution
of [cx3-P]dCTP (Amersham International. Buckinghamshire,
UK); and 0.5 units Taq DNA polymerase (Boehringer); over-
laid with one drop of mineral oil (Sigma, Poole, UK). The
PCR programme was 27 cycles of 94'C for 30 s. 55'C for 30 s
and 72'C for 1 min. incorporating [X32PJdCTP (Amersham).
Point mutations were detected by running the amplification
product of a given exon on 8% non-denaturing acrylamide
gels with 10% glycerol at 24'C for exon 5 or 5% non-
denaturing '2% C' (Hayashi, 1991) acrylamide gels with 5%
glycerol at 20'C for exons 6-8. A negative (no template)
control was 'amplified' and run to detect PCR contamination
and positive controls (samples with known mobility shifts)
were run on each gel. Electrophoresis was done on the LKB
2010 Macrophor Sequencing System (LKB-Produkter.
Bromma, Sweden) using a water-cooled thermostatic plate
and the gels were then soaked in tap water for 15 min to
prevent them adhering to the photographic film. After drying
the gels were exposed at room temperature to Fuji RX film
(Fuji Photo Film, Nomiya, Japan) to obtain a suitable
autoradiograph (3-24 h).
Direct sequencing
Five pmol of each of the following pairs of primers were
used:
exons 5 and 6 5'-TGTTCACTTGTGCCCTGACT-3'
5'-GGAGGGCCACTGACAACCA-3'
exon 7 5'-CAGGTCTCCCCAAGGCGCACTGGCC-3'
5'-TGTGCAGGGTGGCAAGTGGC-3'
exon 8 5'-TGGGAGTAGATGGAGCCTGG-3'
5'-AGGAAAGAGGCAAGGAAAGG-3'
The PCR programme was 30 cycles of 94°C for 2 min,
60°C for 2 min and 72°C for 3 min. The antisense primer was
biotinylated (exon 6, King's College, London; exons 5, 7 and
8, Genosys Biotechnologies, Cambridge, UK) at the 5' end to
enable purification of the single-stranded template using
streptavidin-conjugated magnetic beads (Dynabeads M-280
Streptavidin, Dy-al, Wirral, UK). The sequencing reactions
were done with a 'Sequencing Kit (Pharmacia Biosystems,
Central Milton Keynes, UK) using [a3SJdATP (Amersham)
and the sense primer for each exon (exon 6 was sequenced
using an additional internal sense primer 5'-
TGGTTGCCCAGGGTCCCCAG-3'). The DNA fragments
generated were separated by electrophoresis on 5% denatur-
ing acrylamide wedge gels. All polyacrylamide gel elect-
rophoresis was done with the LKB 2010 Macrophor Sequen-
cing System (LKB-Produkter) and autoradiography was done
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Iby standard methods using Fuji RX photographic film (Fuji
Photo Film, Nomiya, Japan).
Imnnunocytochemistry with thep53 antibody
Ovarian tumours known to have abnormal p53 expression
and previously investigated with CMI antibody under the
same conditions were used as the positive controls with each
batch of lymphoma sections. Negative controls with (a) no
CMI antibody and (b) ovarian samples known to be negative
were also prepared. In the samples of Hodgin's disease the
malignant component of the tissue (Reed-Stemnberg cells or
variants) was used to score the p53 expression. Formalin-
fixed, paraffin-embedded lymphoma sections of 5pm were
prepared by the Department of Pathology, Aberdeen Royal
Infirmary. The sections were left to dry onto 0.1% poly-L-
lysine (Sigma, St Louis, MO, USA)-coated sldes overnight at
room temperature. The sections were dewaxed in xykne and
dehydrated in 100% alcohol. Endogenous peroxidase ativity
was blocked by methanol-hydrogen peroxide. The section
was then preincubated with 20% normal swine serum (Dako,
A/S, Glostrup, Denark). CMI polyclonal antibody (a gift
from Dr DP Lane, Department Biochemistry, University of
Dundee, UK), used as a 1:1000 dilution, was incubated
overnight. The avidin-biotin-peroxidase complex method
was used (Hsu et al., 1981). After development with
diammobenzikine the sections were counterstained with
haematoxylin, dehydrated and mounted.
Redt
p53 mutations
All types of lymphoma were analysed for mutations in exons
5-8. Thirty-three cases of NHL (nine high-grade, 24 low-
grade) and five cases of Hodgkin's disease were studied.
SSCP analysis was used to screen the 38 samples for single
base changes, detected because of the different migation
patterns of the wild-type and mutant radiolabelled DNA
products when denatured and separated by polyacrylamide
gel electphoresis under non-denaturing conditions. This
screening method is fast, specific and sensitive (Gaidano et
al., 1991). To confirm and identify the abnormal nature of
the DNA products of four samples showing band mobility
shifts, direct sequencing was done and showed one silent and
three missense mutations. Figure 1 shoes typical abnormal
band mobility shifts in the SSCP analysis and Figure 2 shows
the silent mutation in a case of Hodgin's disease. Table I
shows the results of the immunocytochemistry by disease
subtype. Table H details the four cases where a point muta-
tion was characterised and shows the degree of CM1
antibody positivity for each case.
Three missnse mutations were characteised (Table II) in
diffieent subtypes of B-cell NHL (one high-grade and two
low-grade). The silent mutation (Figure 2) was a case of
lymphocyte-depleed Hodgkin's disease, which was predic-
tably CMI negative. Case 22 (B-lymphoplasmacytoid NHL)
was negative for CMI aining, although the mutation caused
glycine to be substituted for the wild-type cysteine at codon
135. This tumour sample also showed allele loss at the
YNZ22 ocus 20cM telomeric to p53 (data not shown) when
examined by Southern analysis. It was uninformative for
markers close to p53 (BHP53 and MCT35.1 - data not
shown). The region of chromosome 17p defined by YNZ22
has been impicated with the control ofp53 expression (Coles
et al., 1990).
Tabe I p53 protin expsson asured by CMI polyconal anti-
body staining, with breakdown of lymphoma subtypes (subtypes not
examined are omitted from the table)
Proportion of Quwiication
Histolgical type posrie cases/ of the p53
(Kiel cah ) cases pasiivity
Non-Hodkin's lymphoms
Low-grade B cel
B-CLL 1/4 + +
B4ymphoplasmacytoid 0/3
C entoblasticntic
(inluding B-foificular) 1/14 ++
Low-grade T-c
Angimmunoblastic
lymphadenopathy 0/2
An other types 1/1 +
Hgh-grade B-cell
B-centrblatic diffuse 3/5 +/+ +/+ +
B-mmunoblastic 2/2 +/+++
High-rade Tcell
al types 0/2
Hodkin's d&Eae
Lymphoyte 0/1
Nodular sclerosis 1/1 +
Mixed cellularity 0/2
Lymphocyte depletion 0/1
+, <5%oftumourcelspositiveforCMI stinin; ++, >5%
of tumour ces positiw for CMI staining; +++, >>5% of
tumour cells positive for CMI stainig
T
105 106 22w 27- 36 - 49* 101W
Figwe 1 SSCP analysis, exon 5, p53. +, positive controL Cases
with a mobility shift.
C
C
G
C C
Codon 224
Codon 223
u2oT Cedon 222 Pro -4 Pro
A L G
Flge 2 Direct sequening of sample 39 (Hodgkin's disease,
lymphocyte depleted) showig a siknt mutation m the third last
codon of exon 6 of p53.
p53 mdatm nd Iilp
0II' intjmqjh. $w DJA Adaffison etal
.,i. ......p53.mob"nd uui.I,pksp
DJA Adbson eta
153
Table n Summary oflymphoma point mutation analysis and immunocytochemistry
Case Clinical CMI
reference Sex/age Lymp rma type Codon Exon Nucleotide Amino acid stage positiity
39 M/51 Hodgkin's disea 222 6 CCG-)CCT Silent I B 0
Qympbocyte depeted) (Pro-*Pro)
22 M/44 B-Lympoplasmacytoid 135 5 TGC+GGC Cys-)-Gly IV 0
27 F/49 B-CLL 133 5 ATG-+ATT Met-Ole I >5% (+ +)
47 M/56 B-immunoblastic - 258 7 GAA+AAA Glu-Lys IV >>5% (+ + +)
hibgrd
Immwwcytochemistry
CMl positivity, suggesting abnormal expression or stabilisa-
ton of p53 protein, occurred in 8/33 (24%) cases of NHL
and one case ofHodgin's disease (n = 5). CMl staining was
positive in seven cases in which no point mutation was
det ted.
Burkitt's lymphoma has been quite extensively analysed for
point mutation of p53 (Gaidano et al., 1991; Bhatia et al.,
1992), but other lymphomas have not been so well charac-
teised, although one study (Ichikawa et al., 1992) of point
mutation in exons 5-8 in B-cll Iymphoma identified muta-
tion in 9/48 patients. Eight of these patients had advanced
disease (stage IV). Kocialkowski et al. (1995) have found
mutations in exons 4 and 10 (3/10 positive cases out of 22
cases of high grade NHL). Abnormalities of p53 have been
linked to progression in follicular lymphomas (Lo Coco et
al., 1993) and one study found that a majority of tumours
with point mutation also had abnormal p53 expression
(Sander et al., 1993). Wada et al. (1993) found that only 2%
(8/330) ofchildhood lymphoid malignancies had mutated p53
(exons 5-8), but 2/8 of these mutations were in B-cell NHL.
Abnormally expressed p53 has been detted in
Reed-Sternberg cells in Hodgin's disease (Gupta et al.,
1992) and has been found to be associated with point muta-
tion (Trimper et al., 1993). The latter group used single-cell
analysis, which avoids the sensitivity problems caused by the
large number of non-malignant cells in this diease.
There are several reasons why abnormal
immunocytochemistry may not always correlate with point
mutation ofp53. Immunocytochemical negative results might
be caused by gross deletion of the p53 gene, ladinng to
abolition of protein production, but this is likely to be rare,
and even a mutation inserting a stop codon would probably
cause production of enough p53 protein to be detectable by
CMI. Splice site mutation, such as that reported in chronic
myeloid leukaemia (Foti et al., 1990), might lead to a
dreased availability ofepitopes for the antibody to bind to,
giving a negative result in the presence of a mutation. Apart
from technical artifact, another possibility is that the point
mutation does not stabiise the protein sufficiently to raise its
concentration to a level that can be detected by CM1
immunocytochemistry. Evidence for this argument is pro-
vided by aperinments which show that the strong uniform
saining of thyroid cancer cell lines becomes weaker or
undetectable when such cell ines are grown as tumours in
immunodeficient hosts. The positive staining returns when
the cells are regrown in culture (Wynford-Thomas, 1992). In
addition, a non-mutational mechanism for p53 stabilisation
has been proposed for those benign tssues which
occasionally have positive staining for p53 (Vilhuendas et al.,
1992).
Seven out of nine of those tumours staining positive
showed no point mutation in exons 5-8 of p53, and one of
the three lymphomas with missense mutations showed no
positivity with CMI immunocytochimistry (sample 22).
Lymphoma may be a disease which has an atypical spectrum
ofmutations outwith the exons usually involved in neoplasia,
such as exons 4 and 9, which were not analysed for point
mutation in this study. Kocialkowski et al. (1995) have dem-
onstrated that this is the case in at least some cases of
high-grade NHL. In addition, it is possible that the design of
our exon 5 primers allowed some point mutations to remain
undetected. Alternatively, positive immunocytochemistry
apparently without point mutation could be attributed to
insenstivity of the SSCP analysis or the direct sequencing of
mutated exons when the presence of normal DNA masks the
abnormality. Against this, however, is the finding of positive
immunocytochemistry in cmnal cell hnes which have no p53
mutation - in addition, p53 may be stabilised by ras and
thereby cause positive immunocytochemistry without gene
mutation (Wynford-Thomas, 1992). If such stabilisation of
p53 protein occurs regularly in vivo without mutation of the
gene then immunocytochemistry may provide more inform-
ation about the neoplastic potential of a tumour than muta-
tion analysis would.
Positive p53 immunocytochemistry may be associated with
more aggesve neoplasia in lymphoma (Viluendas et al.,
1992) and prostatic carcinoma (Visakorpi et al., 1992). How-
ever, we would agree with other groups (Nakamura et al.,
1993; Kocialkowski et al., 1995) that, despite the association
between p53 expression and mutation in certain tumours,
immunocytochenistry cannot be used to determine which
tumours have mutations ofp53. Soini et al. (1992) found that
the majority of their tumours which had abnormal p53 exp-
ression were ofhigh-grade type. Although the use ofarchival
material may have influenced the sekction of tumours
studied, it is interesting that in this study 5/9 'high-grade'
NHL tumours but only 3/24 'low-grade' NHL tumours
stained positive for p53.
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